Opinion of the Transparency Council – cetuximab
At its meeting on 16 June 2025, the Transparency Council adopted opinion No. 109/2025 regarding the reimbursement of medicinal products containing the active substance cetuximab, funded under the chemotherapy drug catalogue in Annex No. C.95.b, in terms of indications for use, dosage, or method of administration differing from those specified in the Summary of Product Characteristics